Nature's Sunshine Products Third Quarter 2026 Earnings Call - NATURES SUNSHINE PRODUCTS INC

Financial Performance:

• Q3 2026 net sales totaled $116.6 million, representing a 9% year-over-year decline (7% organic, minus 2% unfavorable foreign exchange).
• Gross margin decreased to 72.9% from 73.3% in the prior year, primarily driven by foreign exchange headwinds.
• Adjusted EBITDA fell to $11.1 million from $15.2 million year-over-year, reflecting lower revenue despite disciplined expense management.
• Selling, general, and administrative (SG&A) expenses were $42.3 million, down from $45.7 million in the prior year.
• Operating cash flow was $10.8 million, down from $18.5 million in the prior year.
• Balance sheet remains robust with $89.4 million in cash equivalents and zero debt.
• Share repurchase activity saw 232,000 shares bought for approximately $3.5 million, leaving $11.3 million remaining on the authorization (note: transcript mentions "$3.5 billion" which appears to be a transcription error given the cash balance; context suggests $3.5 million).
• Subscription auto-ship trends strengthened, accounting for 40% of total digital sales (up from 30% last year).

Guidance and Future Outlook:

• Full-year 2026 net sales outlook lowered to $460–$470 million; previously $450–$500 million.
• Full-year 2026 adjusted EBITDA outlook lowered to $44–$48 million; previously $48–$52 million.
• China expected to remain a significant headwind through 2027 due to leadership transitions and compliance adjustments.
• Long-term strategic goal remains to double company size to $1 billion in sales and achieve a 15% EBITDA margin over time.
• Q4 2026 gross margin guidance projected in the low 72% range, impacted by continued unfavorable foreign exchange.

Business Segments and Product Lines:

• Asia-Pacific: Total sales $55 million (-11% constant currency); China sales plummeted 52% due to leader deaths and compliance crackdowns; Taiwan sales declined after years of growth; Japan and Korea continued growth but failed to offset regional weakness.
• North America: Sales $34 million (-6%); digital business declined 1% YoY after normalizing growth and lapping viral products; U.S. direct selling business remains soft.
• Europe: Sales $22.1 million (+1% constant currency); growth in Eastern Europe (+7%) offset by weakness in Central Europe; Germany launch on track.
• Digital/Strategy: North America adopting an "A-N-D" (Additive) strategy to grow both direct selling and e-commerce simultaneously.
• Product Launches: Launch of "Lunea" (women's health) across Asia; gut health product lineup planned for U.S. direct selling relaunch in 2027; skincare line expansion in Asia.

Market and Competitive Landscape:

• Digital traffic challenges identified due to new AI agents affecting paid search effectiveness; company investing in SaaS tools to adapt.
• Taiwan market identified as mature and declining, requiring new recruiting efforts to reverse trend.
• Japan positioned as a key growth engine with expansion to a third consultant base (Osaka) planned for 2027.
• M&A activity focused on larger targets ($100M+ revenue) to drive meaningful P&L impact; recent $20–$50M targets deemed insufficient despite fit on cost synergies.
• Market trends favor gut health and women's health; company aims to capture share in these high-growth categories.

Risks and Challenges:

• China: Loss of key regional leadership and disruption from enforcing compliance on selling practices have caused long-term revenue impacts expected to last into 2027.
• Digital Normalization: Rapid growth in social commerce (TikTok) and viral products has created difficult comparisons, slowing the rate of digital growth.
• Taiwan: Persistent decline in the consultant base and market saturation.
• Competitive/Regulatory: Potential delays in new Asian market licensing approvals.
• Operational: Transitioning the U.S. direct selling business to a new compensation plan and product lineup requires careful execution to avoid further softness.

Management Commentary and Tone:

• CEO Ken Romanzi admitted the quarter was "poor" and "disappointing," falling well short of expectations.
• Tone remains "bullish" on the long-term vision despite acknowledging the need for "a few quarters" to repair business momentum.
• New CFO Ruth Perkins expressed confidence in the company's 50-year heritage, brand strength, and manufacturing platform.
• Management emphasized a focus on disciplined expense management and rebuilding the productive consultant base.

Analyst Questions and Answers:

• Susan Anderson (Canaccord Genuity): Asked about digital slowdown drivers and China disruptions. Management explained TikTok growth normalization, AI agent impact on paid search, and China's dual issues of leadership loss and compliance tightening.
• M&A Strategy: Anderson asked about M&A; Management clarified they rejected a target due to shaky revenue profiles despite cost synergy potential, and will now proactively seek larger ($100M+) deals rather than waiting for inbound leads.
• Andrew Tompkins (DA Davidson): Asked about Japan growth normalization and innovation pipeline. Management clarified Japan's previous 50% growth was an outlier, new Osaka base is opening, and future growth relies on new women's health and gut health product bundles.

Other Key Points:

• Nature's Sunshine has a 50-year heritage in herbal expertise and a vertically integrated manufacturing platform.
• The company is preparing to launch a new Asian country pending government licensing approval.
• The U.S. direct selling relaunch in mid-2027 will feature a completely new product lineup, compensation plan, and recruiting incentives.
• The company is investing in SaaS tools to improve search, merchandising, and subscription capabilities to counter AI-driven search changes.